Brief: Ocumension Therapeutics Initiation Of Second Phase 3 Clinical Trial Of OT-301 In U.S.
11/11/2020 12:01
Nov 11 (Reuters) - Ocumension Therapeutics 1477.HK :
* SECOND PHASE III CLINICAL TRIAL OF OT-301(NCX 470)
INITIATED IN
U.S. BY GROUP'S LICENSING PARTNER, NICOX S.A.
Source text https://bit.ly/36netOR
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application